 Home > Active Ingredient News > Infection > JAMA: The addition of P2Y12 inhibitors to heparin therapy is not beneficial for improving the prognosis of hospitalized patients with new coronary pneumonia

JAMA: The addition of P2Y12 inhibitors to heparin therapy is not beneficial for improving the prognosis of hospitalized patients with new coronary pneumonia

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

major allergens

hr support

compound non examples

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The COVID-19 pandemic has brought unprecedented challenges to the global healthcare system
.
While most hospitalized patients are not critically ill and do not require intensive care-level medical support, multiple randomized clinical trials have shown that 24% of noncritically ill patients died or received intensive care treatment after receiving therapeutic doses of heparin, whereas Abnormal coagulation function is more common in critically ill patients with new coronary pneumonia , suggesting that new treatment methods are needed for critically ill patients with new coronary pneumonia

COVID-19 COVID-19 Researchers recently examined the benefits and risks of adding a P2Y12 inhibitor to anticoagulation in non-critically ill patients hospitalized with Covid-19

The mean number of days without organ support was 21 days (range 20-21) in the 2Y12 group and 21 days (range 21-22 days) in the control group, with an adjusted OR=0.

For non-critically hospitalized patients with new coronary pneumonia, adding a P2Y12 inhibitor to the therapeutic dose of heparin will not improve the patient's prognosis, but will increase the patient's risk of major bleeding
.
For non-critically hospitalized patients with new coronary pneumonia, adding a P2Y12 inhibitor to the therapeutic dose of heparin will not improve the patient's prognosis, but will increase the patient's risk of major bleeding
.

Original Source:
Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non–Critically Ill Hospitalized Patients With COVID-19 A Randomized Clinical Trial.
JAMA Comments Here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Quality Pidotimod CAS 121808-62-6 Powder Fast Shipping Best Price

CAS No.: 121808-62-6

Pharmacy Grade

$90-100/KG FOB

Phenol CAS NO. 108-95-2 Factory Supply 99% High Quality liquid

CAS No.: 108-95-2

Industrial Grade

$1-1.2/KG FOB

High Quality Trichloroisocyanuric acid 90% powder tabella particle 87-90-1 -Shaanxi Dideu Medichem Co.Ltd

CAS No.: 87-90-1

Chemical Grade

$1/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.